SRX Global Says UC Davis Activated As Clinical Trial Site For CERTAIN-T, Ongoing Phase 1 Study Evaluating CER-1236 In Patients With Hematologic Malignancies Being Conducted By CERo Therapeutics

Loading news article.

SRX Global Says UC Davis Activated As Clinical Trial Site For CERTAIN-T, Ongoing Phase 1 Study Evaluating CER-1236 In Patients With Hematologic Malignancies Being Conducted By CERo Therapeutics | WAPE

SRX Global Says UC Davis Activated As Clinical Trial Site For CERTAIN-T, Ongoing Phase 1 Study Evaluating CER-1236 In Patients With Hematologic Malignancies Being Conducted By CERo Therapeutics

Article summary

Related companies

Analyzed by WAPE AI.

Comments —